
Loading, please wait...

Loading, please wait...

Selective macroautophagy serves as a vital pillar of the innate immune defense against viral pathogens. This process relies on specialized receptors to recognize viral components and shuttle them toward lysosomal degradation. However, a groundbreaking study has revealed a sophisticated method of coronavirus NSP5 autophagy evasion. Researchers discovered that the viral protease NSP5 targets the selective autophagy receptor CCDC50 to ensure viral survival and replication.
CCDC50 was previously characterized for its role in regulating interferon signaling. However, this recent research identifies it as a potent antiviral factor specifically targeting the porcine deltacoronavirus (PDCoV). The receptor recognizes the K63-linked polyubiquitinated envelope (E) protein of the virus. By binding to lysine 72 of the E protein, CCDC50 mediates its degradation through the autophagic pathway. Interestingly, this mechanism operates independently of well-known receptors such as SQSTM1/p62 and NBR1.
The virus has evolved a clever counter-strategy to protect its structural proteins. The NSP5 protease, which is essential for viral polyprotein processing, cleaves the CCDC50 receptor at a specific glutamine 171 (Q171) residue. This proteolytic cleavage is not limited to PDCoV. It is also a conserved feature among other coronaviruses, including SARS-CoV-2 and porcine epidemic diarrhea virus (PEDV). Consequently, coronavirus NSP5 autophagy evasion occurs because the cleavage prevents CCDC50 from interacting with ubiquitin and MAP1LC3/LC3. As a result, the viral envelope protein remains intact, facilitating productive infection.
Understanding these molecular interactions provides a deeper insight into how coronaviruses subvert host immunity. Since the NSP5 cleavage site in CCDC50 is highly conserved across multiple coronavirus species, it represents a potential broad-spectrum therapeutic target. Inhibiting this specific cleavage could restore the host's natural ability to degrade viral proteins. Furthermore, this discovery emphasizes the critical role of selective autophagy in controlling zoonotic and human coronavirus outbreaks.
CCDC50 acts as a selective autophagy receptor. It recognizes the viral envelope protein and delivers it for lysosomal degradation to limit viral replication.
NSP5 cleaves the CCDC50 receptor at the Q171 site. This action disrupts the receptor's ability to link viral proteins to the autophagy machinery, allowing the virus to replicate unchecked.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding medical conditions. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New research shows how coronavirus NSP5 protease cleaves the CCDC50 receptor, allowing the virus to evade selective autophagy and promote replication....
6 months ago

Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today

A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today